0001415889-13-001820.txt : 20130913 0001415889-13-001820.hdr.sgml : 20130913 20130913175328 ACCESSION NUMBER: 0001415889-13-001820 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20130912 FILED AS OF DATE: 20130913 DATE AS OF CHANGE: 20130913 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001070494 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 061376651 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-558-2871 MAIL ADDRESS: STREET 1: 3911 SORRENTO VALLEY BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: KAPLAN LESTER J PH D CENTRAL INDEX KEY: 0001016364 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-50768 FILM NUMBER: 131097206 MAIL ADDRESS: STREET 1: 2525 DUPONT DRIVE CITY: IRVINE STATE: CA ZIP: 92715 4 1 form4-09132013_020918.xml X0306 4 2013-09-12 0001070494 ACADIA PHARMACEUTICALS INC ACAD 0001016364 KAPLAN LESTER J PH D 11085 TORREYANA ROAD #100 SAN DIEGO CA 92121 true false false false Common Stock 2013-09-12 4 M 0 50 6.10 A 8550 D Common Stock 2013-09-12 4 M 0 6500 8.85 A 15050 D Common Stock 2013-09-12 4 M 0 5084 8.85 A 20134 D Common Stock 2013-09-12 4 M 0 10000 9.04 A 30134 D Common Stock 2013-09-12 4 M 0 10000 2.16 A 40134 D Common Stock 2013-09-12 4 M 0 34722 2.16 A 74856 D Common Stock 2013-09-12 4 S 0 66356 22.9018 D 8500 D Stock option (right to buy) 6.10 2013-09-12 4 M 0 50 0 D 2014-06-13 Common stock 50 4450 D Stock option (right to buy) 8.85 2013-09-12 4 M 0 6500 0 D 2015-06-09 Common stock 6500 0 D Stock option (right to buy) 8.85 2013-09-12 4 M 0 5084 0 D 2015-06-09 Common stock 5084 0 D Stock option (right to buy) 9.04 2013-09-12 4 M 0 10000 0 D 2016-06-12 Common stock 10000 0 D Stock option (right to buy) 2.16 2013-09-12 4 M 0 10000 0 D 2019-06-11 Common stock 10000 0 D Stock option (right to buy) 2.16 2013-09-12 4 M 0 34722 0 D 2019-06-11 Common stock 34722 0 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in 2013. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.64 to $23.30 per share, inclusive. The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following March 12, 2004. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 10, 2005. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 13, 2006. 25% of the shares subject to the Stock Option vested and became exercisable at the end of each 3-month period following the date of grant of June 12, 2009. /s/ Glenn F. Baity, Attorney-in-Fact 2013-09-13 EX-24 2 ex24-09132013_020919.htm POWER OF ATTORNEY

POWER OF ATTORNEY



Know all by these presents, that the undersigned hereby authorizes Uli Hacksell, Thomas H. Aasen, Glenn F. Baity or Kirk V. Crawford to execute for and on behalf of the undersigned, in the undersigned's capacity as a director of ACADIA Pharmaceuticals Inc. (the "Company"), Forms 3, 4 and 5 and any Amendments thereto, and cause such form(s) to be filed with the Securities and Exchange Commission pursuant to Section 16(a) of the Securities Exchange Act of 1934, relating to the undersigned's beneficial ownership of securities in the Company.  The undersigned hereby grants to such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or substitute or substitutes of such attorney-in-fact, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted.  The undersigned acknowledges that the foregoing attorney-in-fact, in serving in such capacity at the request of the undersigned, is not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934.


This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorney-in-fact.


IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed this 5th day of September, 2013.




/s/ Lester Kaplan

Lester Kaplan